SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 92 of 94
Word Count: 1490
Character Count: 9556

Document Content:

the Series A Secured Convertible Notes. The Series A Secured Convertible Notes accrue interest at the annual rate of 15% compounded quarterly and have a maturity date of December 31, 2027. The Series A Secured Convertible Notes will automatically convert into shares of our Series A Preferred Stock immediately prior to the closing of this offering (assuming gross proceeds of $7,500,000 to us in this offering), which Series A Preferred Stock is then subject to immediate mandatory conversion into Common Stock at a conversion rate equal to the greater of (A) the then effective conversion rate as calculated pursuant to Section 5 of the Third Amended and Restated Certificate of Incorporation, as amended or (B) the original issue price of the Series A Preferred Stock divided by the price per share of the Common Stock issued in this offering. October 2024 Through March 2026 Series A-1 Secured Convertible Note Financing

From
October 2024 through March 2026, we issued $7,875,000 in principal amount of secured convertible promissory notes (the “Series
A-1 Secured Convertible Notes”) to accredited investors the repayment of which is secured by a grant of security interest in all
of our assets which security interest is pari passu to the security interest granted to the Secured Convertible Note holders. The Series
A-1 Secured Convertible Notes accrue interest at the annual rate of 15% compounded quarterly and have a maturity date of December 31,
2027. As part of the Series A-1 Secured Convertible Note financing, we filed a Certificate of Designations of the Rights, Preferences
and Privileges of Series A-1 Preferred Stock which designated a new Series A-1 Preferred Stock from its authorized Blank Check Preferred
Stock. The Series A-1 Secured Convertible Notes automatically convert into shares of Series A-1 Preferred Stock at the conversion price
of $3.33 per share immediately prior to the closing of this Offering (assuming gross proceeds of $7,500,000 to us in this offering),
which shares of Series A-1 Preferred Stock are then subject to immediate mandatory conversion into Common Stock at a conversion rate
equal to the greater of (A) the then effective conversion rate as calculated pursuant to Section 4.1.1 of the Certificate of Designations
of Rights, Preferences and Privileges of Series A-1 Preferred Stock or (B) three times (3x) the original issue price of the Series A-1
Preferred Stock divided by the price per share of the Common Stock issued in this offering. Therefore, if the offering price is $10.00/share
or greater, each share of Series A-1 Preferred Stock will convert into one share of Common Stock. If the offering price is less than
$10.00/share, then each share of Series A-1 Preferred Stock will convert into the number of shares of Common Stock as calculated by dividing
$9.99 by the offering price. For example, if the offering price is $8.00, then each share of Series A-1 Preferred Stock will get $9.99
divided by $8.00 (1.24875) shares of Common Stock.

April 2026 Series A-2 Secured Convertible Note Financing

Starting in April 2026, we issued $805,000 in principal amount of secured
convertible promissory notes (the “Series A-2 Secured Convertible Notes”) to accredited investors the repayment of which is
secured by a grant of security interest in all of our assets which security interest is pari passu to the security interest granted to
the Secured Convertible Note holders. The Series A-2 Secured Convertible Notes accrue interest at the annual rate of 15% compounded quarterly
and have a maturity date of December 31, 2027. As part of the Series A-2 Secured Convertible Note financing, we filed a Certificate of
Designations of the Rights, Preferences and Privileges of Series A-2 Preferred Stock which designated a new Series A-2 Preferred Stock
from its authorized Blank Check Preferred Stock. The Series A-2 Secured Convertible Notes automatically convert into shares of Series
A-2 Preferred Stock at the conversion price of $5.00 per share immediately prior to the closing of this Offering (assuming gross proceeds
of $7,500,000 to us in this offering), which shares of Series A-2 Preferred Stock are then subject to immediate mandatory conversion into
Common Stock at a conversion rate equal to the greater of (A) the then effective conversion rate as calculated pursuant to Section 4.1.1
of the Certificate of Designations of Rights, Preferences and Privileges of Series A-2 Preferred Stock or (B) two times (2x) the original
issue price of the Series A-2 Preferred Stock divided by the price per share of the Common Stock issued in this offering. Therefore, if
the offering price is $10.00/share or greater, each share of Series A-2 Preferred Stock will convert into one share of Common Stock. If
the offering price is less than $10.00/share, then each share of Series A-2 Preferred Stock will convert into the number of shares of
Common Stock as calculated by dividing $10.00 by the offering price. For example, if the offering price is $8.00, then each share of Series
A-2 Preferred Stock will get $10.00 divided by $8.00 (1.25) shares of Common Stock.

Item
16. Exhibits

The
following is a list of exhibits filed as a part of this registration statement:

Exhibit Number Description of Document

1.1* Form of Underwriting Agreement

3.1* Third Amended and Restated Certificate of Incorporation of BioVentrix, Inc.

3.2* Amendment No. 1 to Third Amended and Restated Certificate of Incorporation of BioVentrix, Inc.

3.3* Amendment No. 2 to Third Amended and Restated Certificate of Incorporation of BioVentrix, Inc.

3.4* Amendment No. 3 to Third Amended and Restated Certificate of Incorporation of BioVentrix, Inc.

3.5* Fourth Amended and Restated Certificate of Incorporation of BioVentrix, Inc., to be in effect upon the consummation of the initial public offering

3.6* Bylaws of BioVentrix, Inc.

3.7** Certificate of Designations of the Series A-1 Preferred Stock

3.8* Certificate of First Amendment of Certificate of Designations of the Rights, Preferences and Privileges of the Series A-1 Preferred Stock

3.9* Certificate of Second Amendment of Certificate of Designations of the Rights, Preferences and Privileges of the Series A-1 Preferred Stock

3.10** Certificate of Designations of Series A-2 Preferred Stock

4.1* Form of Underwriters’ Warrant

5.1* Opinion of Ellenoff Grossman & Schole LLP

10.1* Form of Indemnification Agreement

10.2* 2024 Equity Incentive Plan

10.3* 2026 Equity Incentive Plan

10.4* Form of David Richmond Employment Agreement

10.5* Form of Steve Chartier Employment Agreement

10.6* Lease between BioVentrix, Inc. and Brickman Forbes Boulevard LLC

10.7* Exclusive License Agreement, dated as of December 28, 2021, by and between BioVentrix Inc. and Henry Ford Health System

10.8* Amendment to Exclusive License Agreement, dated as of February 12, 2025

10.9* Investors’ Rights Agreement, dated March 30, 2023, by and among BioVentrix and the other parties thereto

10.10* Form of Lockup Agreement

10.11** Ori Ben-Yehuda Consulting Agreement

10.12** Form of Carl Byrnes Employment Agreement

14.1* Form of Code of Ethics of BioVentrix, Inc.

21.1* List of Subsidiaries

23.1** Consent of M&K CPAS PLLC, Independent Registered Public Accounting Firm

23.2* Consent of Ellenoff Grossman & Schole LLP (contained in Exhibit 5.1)

24.1* Powers of Attorney (included on signature page to this registration statement)

99.1* Form of Audit Committee Charter

99.2* Form of Compensation Committee Charter

99.3* Form of Nominating and Corporate Governance Committee Charter

107* Filing Fee Table

*	Previously
filed.

**	Filed herewith.

Item
17. Undertakings

The
undersigned registrant hereby undertakes:

file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable,
in the effective registration statement.

include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.

2.	That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.

remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.